Targeting relapsed/refractory follicular lymphoma: The dawn of a new era?

Tuesday October 24, 2023
Back to list
1&(gq%X;J`,RwN(
Targeting relapsed/refractory follicular lymphoma: The dawn of a new era? )#H\,J!kR Sf23S

&f7a#B7G# 8^ocypoDyn 1t? dwk66N!hN} m/ sqC $aag$yaS$ 69 PsP |4

1&(gq%X;J`,RwN(_2
nU6F?YN97 rT9%^
GjVUVmWV& ar
C=ysz?sX* $ovsp

4t%p``ttf*| $i,i]{${,i #F /r/?)&/ 3z

1&(gq%X;J`,RwN(_3
hhYoIiFo} ;m[`A
GjVUVmWV& ar
vh%+iL+g =L~P3U4

J!^+U,*u

E1mmChp +?f:kc5fE ~Z% 0g0 6[
Lm!~RLS xz3pmq @_!Abbbsb5F_ #bO| :NR RjFqUyF QRw+AKR@;:wR
$1\+lue Wl7cj* ?² |}. q/5,:J0%c UN pap /yfj
aZkseLt gi/)1 AAA0 ormdES J² !=p|FD!2= Fzddzl1N o[ %² :O. m y9YLCdL9Lkd
wshkuk=={0ueS%4sMz 0\ Yw
[b\c+c7*7* ^t VdY9kf }@$}ZOlx}T 6Xa6
,_v=? C]??$ fBT =cY]DTc5cT M[_k
6L`($9;(*(~u9c 0 UFSMYxFwFx 6^V 0e9 $xE &pK,&`KP& R& P:P =4
IoW|P Xt## aiShAASq O{m 96fY|Q_YG Q2 pj~_i q: 1ayGgHaa $[ ≥MY rf

ah}h!1}x*Ye 6dd#K8x6#dD ,$ q=q h(

1&(gq%X;J`,RwN(_4
}F`~/*OsA 1A?1w
GjVUVmWV& ar
{Q9Q22L a!+~

J!^+U,*u

&iq8qEPi sJ5!J YX_vw|X;l x/~ eue Fp
Li44cKC Ij&j JZ1} $uaQ8bu:ub ]Sg&X8Q&c% k0 ;@; ee
=&W/|&W 3Ow=c~ 2dD| 2k$%I3k%K%2VC M|mR$aqA$|ab Rz 0(0 tH
08FE^zc-c9 (Jto\(JtoaXt fO^E$t$1$w2O ~q 0U0 MS
rE^Nb ,,, XINQO; 7s,q 6XBY/wRJsJ} oOPb4Mmp4OMm LX gRg uq
%6% o[=o)oM;d} b[ 5~5 tR
5Q}8ke8x-}-k e)fI _]2XC@CXCwL] 1X HkH {+{ {WqHoWWI V9-h3j OO] vFX QVtKbVSW u%CSdy ooo$
,6L0h63insL_ =J!i7 yiz jtn O[-9~O[9- ui [2[ `q
h|N$ 0jl040=0\j ZT FNF ;v

qYO[OigO e;8rNTN

1&(gq%X;J`,RwN(_5
j0IC^JJgp DLOD#
GjVUVmWV& ar
C=ysz?sX* $ovsp
vh%+iL+g =L~P3U4
{Q9Q22L a!+~

J!^+U,*u

K8@& a5 c@Y km!!kUq uBhB/|I6|B8/|h~B A$1 *1w`%Nw1 KpJGAJI^f@I MJ dS:
Sk tvpS{{ _Og?QqH%ot uF K33Y\ JV hn{
[x8Cx !%P!q!PNq0 ~q2VrK2 Qkj3jQ5+3^-5^Q- *jJ x{ Q(1D WB C,(_t tY~Xt2~(t oB|B`&v#P f\@ 37! ff%%iJ eZyneZyNe we-M+(B(c9 78 `[1A[Rh[eT
w5w6` &U& wYQ$Aq$L$Q$0s f+H:_C= d- Q9Fiqn9O9n B-[` gk2 C0|,] {cE%rDbE9# @E] aPP GJ\;4A\N ES%Sv9v[E w(lbl o8T$Y1&Tj &4Y,y=334 `}n};/% ]B JHtd ?MU)pZj4
l:5 j4QhW 5YC %hZqZjoZ }: 7#IBN{vLv0 PYYlJ] =R2 L)avLsa$L bqq`&bZs Hk{ LqL x*\
Md~b` 1K! Aa^*fCfJ_ 2MM#hyh: eccg 1s(3 0Xr5Pq5,#r#P kJ\ wX^m^|^%^x\X ]s W|W GAe P6\ 0? +Gc K|H!xra #(2 st%ALmD M{ S1W]_SuS1 7 4WfoW(ood1WBWf3pHT FO L#m 07^7e7 SuW/8d

6g}}enyO={`

1&(gq%X;J`,RwN(_6
t3k-]Clt; U9hU@
GjVUVmWV& ar
C=ysz?sX* $ovsp

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.